Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicines set out in the Schedule hereto:
Schedule
Product: Elaprase
Active Ingredient: Idursulfase 2mg/mL
Dosage Form: Concentrate for infusion
New Zealand Sponsor: Pharmacy Retailing (NZ) Limited t/a Healthcare Logistics
Manufacturers: Baxter Pharmaceutical Solutions LLC, Bloomington, Indiana, United States of America
Genzyme Corporation, Allston, Massachusetts, United States of America
Note: This consent is valid for two years from the date of publication of this notice.
Product: Isentress
Active Ingredient: Raltegravir potassium equivalent to Raltegravir 400mg
Dosage Form: Tablet
New Zealand Sponsor: Merck Sharp & Dohme (New Zealand) Limited
Manufacturer: Merck & Co Inc, Stonewall Plant, Elkton, Virginia, United States of America
Note: This consent is valid for two years from the date of publication of this notice.
Dated this 28th day of August 2008.
JOHN HAZELDINE, Acting Deputy Director-General, Sector Accountability and Funding Directorate (pursuant to delegation given by the Minister of Health on 6 July 2001).